{"id":13077,"date":"2026-05-01T01:44:59","date_gmt":"2026-05-01T01:44:59","guid":{"rendered":"https:\/\/globalnewstoday.uk\/index.php\/2026\/05\/01\/potential-biological-targets-for-vascular-dementia-lab-life-scientist\/"},"modified":"2026-05-01T01:44:59","modified_gmt":"2026-05-01T01:44:59","slug":"potential-biological-targets-for-vascular-dementia-lab-life-scientist","status":"publish","type":"post","link":"https:\/\/globalnewstoday.uk\/index.php\/2026\/05\/01\/potential-biological-targets-for-vascular-dementia-lab-life-scientist\/","title":{"rendered":"Potential biological targets for vascular dementia – Lab + Life Scientist"},"content":{"rendered":"

Caused by damage to blood vessels in the brain, there is currently no approved treatment for vascular dementia. Could genetics-led approaches offer pathways to future therapies?
Potential biological targets that could help guide future research into treatments for vascular dementia have been identified in a study by UNSW Sydney\u2019s Centre for Healthy Brain Ageing (CHeBA<\/a>) that was funded by the Dementia Australia Research Foundation (DARF) Royce Simmons Project Grant and published open access (doi.org\/10.1002\/trc2.70258<\/a>) in a journal of the Alzheimer\u2019s Association, Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions<\/em>.
Vascular dementia is the second most common form of dementia worldwide, accounting for around 15\u201320% of all cases, and is caused by damage to blood vessels in the brain. Despite its prevalence and impact, currently, the condition has no approved treatments in Australia.
\u201cVascular dementia is a major and growing public health problem. It affects memory, thinking and function, yet we have no effective treatments to stop or slow its progression. Our study provides an initial step by identifying biologically plausible targets that could inform future research into therapies,\u201d said lead author of the study Dr Matthew Lennon<\/a>.
Genetic approach Mendelian randomisation was used in the study to analyse more than 12,000 potentially \u2018druggable\u2019 genes. Along with the proteins they produce, these genes could be targeted by medications. The team identified genes that may play a causal role in vascular dementia by examining large-scale genetic datasets from hundreds of thousands of individuals.
Four such genes were identified and linked to vascular dementia risk in the study. These were APOE and TOMM40 \u2014 well-established genes already known to play roles in brain health and dementia \u2014 and ERAP and SAA1-4 \u2014 linked to inflammation and immune processes, these are newer, emerging targets.
APOE and TOMM40 were the two strongest signals and associated with brain imaging markers of small vessel disease, a major contributor to both vascular dementia and Alzheimer\u2019s disease. The researchers said this strengthens the evidence that these genes are involved in underlying disease processes.
As to the importance of this study, the researchers said that vascular dementia research has lagged behind research into diseases like Alzheimer\u2019s disease, where several treatments exist and many more are in development \u2014 something that has left patients with limited options.
\u201cManaging risk factors like blood pressure and cholesterol helps, but it\u2019s not enough,\u201d Lennon said. \u201cEven under ideal conditions, prevention strategies may only reduce dementia risk by less than half. We urgently need new avenues for research into targeted treatments.\u201d
It is believed that this gene identification may help inform future research aimed at drug development targeting pathways relevant to vascular dementia; exploration of whether existing medications acting on these genes could be repurposed; and advancing understanding of how vascular and Alzheimer\u2019s disease processes overlap.
Yet, many potential drug targets do not ultimately lead to successful therapies, the researchers emphasised, and translating genetic findings into safe and effective treatments is a complex and lengthy process.
\u201cAt a time when vascular dementia remains a major unmet medical need, this study highlights the potential of genetics-led research to uncover new treatment pathways and bring hope for future therapies,\u201d CHeBA Co-director Professor Perminder Sachdev<\/a> said.
Laboratory studies, additional genetic analyses and clinical trials are among the further work that is needed, the researchers acknowledge, yet they also believe that the study constitutes an important lead for future drug development. \u201cThis is an important first step,\u201d Lennon said. \u201cBy identifying potential targets, we can begin to better understand where future research and drug development efforts might be directed.\u201d
Image credit: iStock.com\/Tonpor Kasa. Stock image used is for illustrative purposes only.<\/h9>
To commercialise its ecopha.bio technology for a Pongamia-based bioeconomy, Australian company…
A thin plastic film that tears apart viruses on contact could help protect high-touch hospital…
By embedding tiny, multi-functional nanomaterials into hydrogel dressing, this smart bandage…
Beyond LIMS: The Paradigm Shift Redefining QC Digital Transformation
<\/a>
Renewables supply reaches almost 50% on Aust's east coast
Quantum timing study to help future-proof energy grid
New method to extract microplastics from soil: study
Water treatment plant receives 'Blue Loan'
Australians need to take care when recycling
<\/a>
Clinical environments are changing. Healthcare solutions must change with them.
Improving care for some of the sickest patients in the hospital: new national standard for emergency laparotomy
Doctors union accuses NSW Health of denying junior doctors study leave
Health Minister's Award for Nursing Trailblazers — nominations open
Pulse technology promises an atrial fibrillation treatment upgrade
<\/a>
Measurement Solutions joins the Bestech Group: a significant step into the process industries
Building grid resilience with quantum timing
Fujitsu and Carnegie Mellon launch joint physical AI research
ABB Robotics launches high‍-‍speed cobot range
WA Government announces $1.4bn clean energy fund
Westwick-Farrow Media
Locked Bag 2226
North Ryde BC NSW 1670
ABN: 22 152 305 336
www.wfmedia.com.au<\/a>
Email Us<\/a>
LabOnline has an editorial mix of business news, research and funding updates, industry comment, feature articles, conference previews, case studies and succinct new product items, making it a ‘must read’ for industry leaders.
SUBSCRIBE TO OUR MEDIA CHANNEL<\/a>
Membership is FREE to qualified industry professionals across Australia.
SUBSCRIBE MAGAZINE<\/a>
For subscription enquiries please <\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Caused by damage to blood vessels in the brain, there is currently no approved treatment for vascular dementia. Could genetics-led approaches offer pathways to future therapies?Potential biological targets that could help guide future research into treatments for vascular dementia have been identified in a study by UNSW Sydney\u2019s Centre for Healthy Brain Ageing (CHeBA) that […]<\/p>\n","protected":false},"author":1,"featured_media":13078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":{"0":"post-13077","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-science"},"_links":{"self":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/13077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/comments?post=13077"}],"version-history":[{"count":0,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/13077\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media\/13078"}],"wp:attachment":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media?parent=13077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/categories?post=13077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/tags?post=13077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}